Wesley Pharmaceuticals, Orlando, FL
Is Wesley Pharmaceuticals an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Wesley Pharmaceuticals in Orlando, FL, first registered Jul 25, 2025 and most recently registered Oct 22, 2026. FDA lists its last inspection as Mar 16, 2026, with no Form FDA 483 issued; FDA lists the action on that inspection as “FMD-145 Letter Issued 6/17/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Orlando, FL
- Initial registration
- Jul 25, 2025
- Most recent registration
- Oct 22, 2026
- Last inspection
- Mar 16, 2026
- Form 483 issued at last inspection
- No
- Recall after last inspection
- No
- Action on last inspection
- FMD-145 Letter Issued 6/17/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Wesley Pharmaceuticals, Orlando, FL (FEI number 3038879280), matched to this page by exact name, city and state. It lists 1 inspection: 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 16, 2026 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3038879280 | 1313212 |
Form 483s FDA has published for this site
No published Form 483 for FEI 3038879280 was found in the dashboard’s list of published 483s on Nov 15, 2026. FDA publishes only some 483s, so this does not mean none was issued.
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Wesley Pharmaceuticals). That is not a finding beyond this index’s search.
The Wesley Pharmaceuticals pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
Records last pulled Nov 15, 2026. Every entry links to the original public record.